Other languages Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
2.55 ^USD	+8.97%		0.00%	+50.00%

Apr. 23	Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	MT
Mar. 21	Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	Mar. 21
Sector Update: Health Care Stocks Slipping Late Afternoon	Mar. 13
Heron Therapeutics Shares Soar After Q4 Results Beat	Mar. 13
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	Mar. 12
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	Jan. 24
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	Jan. 23
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	Jan. 08
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	Jan. 08
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	Jan. 07
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023	Dec. 21
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing	Nov. 17
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024	Nov. 14
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Heron Therapeutics, Inc. Reiterates Net Product Sales Guidance for the Full Year 2023	23-08-14
Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Insider Buy: Heron Therapeutics	23-07-25
Heron Therapeutics Cuts Workforce by 25%	23-07-24
Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company	23-07-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Other languages

Filters